Navigation Links
Researchers Able to Identify that Benign Tumors from Use of Oral Contraceptive Have a Greater Chance of Becoming Malignant
Date:11/3/2013

WASHINGTON, Nov. 3, 2013 /PRNewswire/ -- Although very rare, the use of oral contraceptive can lead to benign tumors in the liver. The tumors, known as hepatocellular adenomas, can become malignant. It is, however, difficult for physicians to assess the risk of these tumors becoming malignant.

The study's researchers examined and classified data from 250 patients with hepatocellular adenomas. They examined classical adenomas (223), borderline lesions between adenomas and carcinomas (18), and carcinomas (9). The data was examined using whole exome sequencing, CGH-SNP analyses, and methylome analyses.

Researchers were able to identify the genetic determinants of malignant transformation as well as the key factors at stages of the transformation. "Our work reported for the first time a molecular mechanism of malignant transformation of hepatocellular adenomas to carcinomas," lead researcher, Camilla Pilati, PhD, said, "Surprisingly, we were able to identify the chronology of the genetic defects that accumulate in hepatocytes to promote their malignant transformation. In this line, we identified genetic alteration that acts at early and late steps of the malignant transformation process, in the accumulation of early genetic alteration at the origin of the malignant transformation of the hepatocytes."

Two genes with somatic mutations -- one in the early stages and one in the later stages -- were identified in the malignant transformation. Mutations of beta-catenin are associated with many forms of cancer, and beta-catenin activation and TERT promoter mutations in the early and later stages, respectively, were identified in the malignancy process. In addition, the researchers were able to identify factors that determined adenomas that were not at a high risk of becoming carcinoma.

"This work provided new insights about the major genetic determinants of malignant transformation and their timeframe accumulation during the adenoma-carcinoma sequence. At the clinical level, we believe that these results open new avenues for personalized medicine in hepatocellular adenomas," said Dr. Pilati.

"The aim of this classification is the identification of new biomarkers useful for a more precise diagnosis and that could be used as therapeutic targets. This is clearly an important step to develop a more personalized medicine with, for example, the selection of patients with high risk of malignant transformation that require a specific follow-up and more radical treatment," Dr. Pilati concluded. "Identification of CTNNB1 and TERT promoter mutation as key genetic determinants of malignant transformation in HCA will be useful to propose tailored treatment in these subtypes of patients.

Abstract title:

Integrative genomic profiling of hepatocellular adenomas identify mutational processes involved in malignant transformation.

AASLD is the leading medical organization for advancing the science and practice of hepatology. Founded by physicians in 1950, AASLD's vision is to prevent and cure liver diseases. This year's Liver Meeting®, held in Washington, November 2-5, will bring together more than 9,000 researchers from 55 countries.

A pressroom will be available from November 1 at the annual meeting. For copies of abstracts and press releases, or to arrange researcher interviews, contact Gregory Bologna at 703-299-9766.

Press releases and all abstracts are available online at www.aasld.org.

Media Contact: Gregory Bologna
703/299-9766  
gbologna@aasld.org
Press Room: November 1 – 5, 2013
Walter E. Washington Convention Center, Washington, DC
Telephone: 202-249-4092

Researcher: Camilla Pilati, PhD
Email: campilati@gmail.com
Phone: 0033 1 53725193

This release was issued through The Xpress Press News Service, merging e-mail and satellite distribution technologies to reach business analysts and media outlets worldwide. For more information, visit http://www.XpressPress.com.


'/>"/>
SOURCE American Association for the Study of Liver Diseases (AASLD)
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Children of lower socioeconomic status grow up more susceptible to catching colds, Carnegie Mellon researchers find
2. University of Louisville researchers sign global licensing agreement
3. BUSM researchers study epigenetic mechanisms of tumor metastasis for improved cancer therapy
4. Researchers quantify toxic ocean conditions during major extinction 93.9 million years ago
5. Researchers discover how cancer invisibility cloak works
6. Oregon researchers say supplement cuts muscle loss in knee replacements
7. BUSM researchers identify molecule that could aid lung cancer detection, treatment
8. Researchers identify gene variant that raises risk for colorectal cancer from eating processed meat
9. Researchers show how plants tell the time
10. Berkeley Lab researchers get a detailed look at a DNA repair protein in action
11. Researchers capture images of open channel that moves proteins across cell membranes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2016)... Research and Markets has announced the addition of the ... offering. ... The global bioinformatics market is ... Billion in 2016, growing at a CAGR of 21.1% during the ... driven by the growing demand for nucleic acid and protein sequencing, ...
(Date:6/22/2016)... June 22, 2016   Acuant , ... verification solutions, has partnered with RightCrowd ® ... for Visitor Management, Self-Service Kiosks and Continuous ... that add functional enhancements to existing physical ... and venues with an automated ID verification ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... 2016  The Multiple Myeloma Research Foundation (MMRF) today ... Study SM —the largest and most comprehensive study driving ... myeloma—will be presented at the 58 th American ... San Diego from December 3-6. ... as well as identify pathways and targets for new ...
(Date:12/2/2016)... -- Research and Markets has announced the addition ... Companies" to their offering. ... , , ... industries is anticipated. Nanotechnology will be applied at all stages ... diagnostic applications in clinical trials. Many of the assays based ...
(Date:12/2/2016)... ... 2016 , ... Aerocom Healthcare ( http://www.aerocomhealthcare.com ), representing the ... chain-of-custody solution for tracking and securing medications at booth 676 at the ASHP ... Aerocom has a proven solution for tracking medications via its system from pharmacy ...
(Date:12/2/2016)... ... 01, 2016 , ... DrugDev believes the only way to achieve ... experience. All three tenets were on display at the 2nd Annual DrugDev User Summit ... sponsor, CRO and site organizations to discuss innovation and the future of clinical research. ...
Breaking Biology Technology: